Academic Journal
View in EDS

Dibutylstannanediyl (2Z,2′Z)-bis(4-(benzylamino)-4-oxobut-2-enoate inhibits prostate cancer progression by activating p38 MAPK/PPARα/SMAD4 signaling

Bibliographic Details
Title: Dibutylstannanediyl (2Z,2′Z)-bis(4-(benzylamino)-4-oxobut-2-enoate inhibits prostate cancer progression by activating p38 MAPK/PPARα/SMAD4 signaling
Authors: Waseem, Durdana, Khan, Gul Majid, Haq, Ihsan-Ul, Syed, Deeba N.
Source: In Toxicology and Applied Pharmacology 15 August 2022 449
Database: ScienceDirect
More Details
ISSN:0041008X
DOI:10.1016/j.taap.2022.116127
Published in:Toxicology and Applied Pharmacology
Language:English